Stifel Nicolaus Keeps Their Buy Rating on Neurogene (NGNE)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Neurogene (NGNE – Research Report) today and set a price target of $46.00. The ...
Spyre Therapeutics (SYRE) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report) today and set a price target ...
Stifel raises Boston Scientific stock target to $120, keeps buy rating
Stifel analysts increased their price target on Boston Scientific Corporation (NYSE:BSX) shares from $115.00 to $120.00, while reiterating a Buy rating for the medical device company. The adjustment ...
Stifel maintains Buy on Denali Therapeutics, $37 target
Stifel analysts confirmed their Buy rating on Denali Therapeutics Inc. (NASDAQ:DNLI) with a steady price target of $37.00. According to InvestingPro data, analysts maintain a Strong Buy consensus with ...